[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353137-105":59,"doc-detail-353137-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-combination-immunotherapy-and-targeted-therapy-as-second-line-and-subsequent-treatments-for-advanced-biliary-tract-cancer-systematic-review-and-meta-analysis","Efficacy and safety of combination immunotherapy and targeted therapy as second-line and subsequent treatments for advanced biliary tract cancer - Systematic review and meta-analysis","","Biliary tract cancer often leads to poor prognosis despite treatment advances. This systematic review and meta-analysis evaluates randomized clinical trials and cohort studies assessing immunotherapy and targeted therapy used as second-line or later treatments for advanced biliary tract cancer. Literature searches across major databases through August 31, 2024 extract outcomes including ORR, DCR, PFS, OS, and adverse events (AEs), to characterize efficacy and tolerability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-combination-immunotherapy-and-targeted-therapy-as-second-line-and-subsequent-treatments-for-advanced-biliary-tract-cancer-systematic-review-and-meta-analysis/353137/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-combination-immunotherapy-and-targeted-therapy-as-second-line-and-subsequent-treatments-for-advanced-biliary-tract-cancer-systematic-review-and-meta-analysis/353137.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the meta-analysis address?","Question",{"text":112,"@type":113},"It assesses the efficacy and safety of combination immunotherapy and targeted therapy given as second-line and subsequent treatments for advanced biliary tract cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and study types were included?",{"text":117,"@type":113},"It includes data from randomized clinical trials and cohort studies, using a systematic search across PubMed, Embase, Cochrane Library, and Web of Science through August 31, 2024.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main efficacy and safety findings?",{"text":121,"@type":113},"The pooled objective response rate (ORR) was 14% and disease control rate (DCR) was 68%. Most adverse events were grade 1–2, with grade ≥3 events reported as low (below 14%), and commonly observed AEs included fatigue, hypertension, and nausea.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353137,1790167535,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","®  \nSystematic Review and Meta-Analysis   \nEfficacy and safety of combination immunotherapy and targeted therapy as secondline and subsequent treatments for advanced biliary tract cancer  \nA systematic review and meta-analysis  \nYiran Liao, MMa , Zhongli Liao, MDb , Jiong Wang, MMb ,*  \n\n| Abstract\u003Cbr>Background: Biliary tract cancer is a highly dangerous cancer that often results in a poor prognosis for patients, even with significant advancements in treatment options. Recent advancements in targeted therapies and immunotherapy have shown great potential in treating various cancers. This underscores the importance of conducting a detailed review and meta-analysis of these approaches specifically for biliary tract cancer.\u003Cbr>Methods: This meta-analysis included data from randomized clinical trials and cohort studies examining the use of immunotherapy and targeted therapies specifically as second-line treatments for patients diagnosed with biliary tract cancer. A comprehensive andsystematic literature search was conducted across prominent databases, including PubMed, Embase, Cochrane Library, and Web of Science, encompassing publications from the inception of these databases until August 31, 2024. Key outcome measures, such as objective response rate (ORR), DCR, progression-free survival, overall survival, and AEs, were meticulously extracted for analysis.\u003Cbr>Results: The findings of this meta-analysis revealed that the ORR across the included studies varied from 4% to 33%, with a combined ORR of 14%(95% confidence interval [CI]: 9%–19%) . The pooled DCR was calculated at 68%(95% CI: 53%-77%) . Median overall survival was reported as 10.75 months (95% CI: 8.23–13.27 months), while median progression-free survival was 4.39 months (95% CI: 2.73–6.04 months) .\u003Cbr>In terms of AEs, most patients experienced only grade 1 to 2 events, indicating a generally favorable tolerance to treatment. The most commonly reported AEs included fatigue (44%, 95% CI: 31%–58%), hypertension (41%, 95% CI: 28%–55%), and nausea (23%, 95% CI: 18%–29%) . Additionally, thrombocytopenia emerged as the most prevalent hematological toxicity, occurring in 31% of patients (95% CI: 23%–39%) . Notably, the incidence of ≥grade III AEs was very low, remaining below 14% . Among the most frequent severe AEs were hypertension and elevated aminotransferases, with incidences of 14% and 8%, respectively. Conclusion: This comprehensive meta-analysis highlights the potential role of targeted therapies and immunotherapy in the management of biliary tract cancer, demonstrating promising albeit moderate efficacy. These findings underscore the necessity for further research and clinical trials aimed at optimizing treatment protocols to enhance outcomes for patients afflicted with this challenging malignancy.\u003Cbr>Abbreviations: AEs = adverse events, ASC = active symptom control, BTC = biliary tract cancer, CI = confidence interval, DCR = disease control rate, eCCA = extrahepatic cholangiocarcinoma, FGFR = Fibroblast growth factor receptor, GBC = Gallbladder cancer, iCCA = intrahepatic cholangiocarcinoma, ICIs = Immune checkpoint inhibitors, IDH = isocitrate dehydrogenase, NOS = Newcastle-Ottawa Scale, ORR = objective response rate, OS = overall survival, PD-1 = programmed cell death protein 1, PFS = progression-free survival. |\n| --- |\n| Keywords: biliary tract cancer, efficacy, immunotherapy, meta-analysis, targeted therapy |\n\nThe authors have no funding and conflicts of interest to disclose. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.  \na Phase I Clinical Research Center, Chongqing University Cancer Hospital, Chongqing China, b Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China.  \n* Correspondence: Jiong Wang, Gastroenterology, Chongqing University Cancer Hospital, Chongqing 400030, China ([email: jiongwang037@126.com](email: jiongwang037@126.com)). ","cbCaibIp4L52PYx7","https://ap.wps.com/l/cbCaibIp4L52PYx7","pdf",1788468,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Abbreviations\n# Introduction\n## Disease overview and epidemiology\n## Clinical prognosis and unmet needs","[{\"question\":\"What question does the meta-analysis address?\",\"answer\":\"It assesses the efficacy and safety of combination immunotherapy and targeted therapy given as second-line and subsequent treatments for advanced biliary tract cancer.\"},{\"question\":\"Which databases and study types were included?\",\"answer\":\"It includes data from randomized clinical trials and cohort studies, using a systematic search across PubMed, Embase, Cochrane Library, and Web of Science through August 31, 2024.\"},{\"question\":\"What were the main efficacy and safety findings?\",\"answer\":\"The pooled objective response rate (ORR) was 14% and disease control rate (DCR) was 68%. Most adverse events were grade 1–2, with grade ≥3 events reported as low (below 14%), and commonly observed AEs included fatigue, hypertension, and nausea.\"}]","Efficacy and safety of combination immunotherapy and targeted therapy as second-line and subsequent treatments for advanced biliary tract cancer - Systematic review and meta-analysis | PDF",1790103263,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7d88b673983c57d2bab8b8fdeb51db5.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6486aba4837b527b7a31718b98332724.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e3c8f283e510c597a89f5a3155d145e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a018945776a86a8f1cd32d4331b4309.webp",980,1306]